Evaluating the place of low-molecular-weight heparin in the management of acute coronary syndromes

James H. Chesebro, FREEK W. A. Verheugt, Frederic Kontny, EDWARD T. A. Fry, Lars Wallentin, A. John CAMM, Heinrich Bechtold
2001 Clinical Cardiology  
Extended low-molecular-weight hepann treatment beyond the acute phase reduces the nkk of deatMmyocatdial infmction (MI) at 30 days in patients with unstable coronary artery disease (UCAD; unskable angina/mn Q-wave MI). Can riskstm@%ation determine which palients willbeneflmost? Highest risk: Primary PCI or lytics GP IlWllla-inhibitor7 Unstable angina Enyzmes neg., ECG neg. Non-Q-wave MI Unstable angina Enzymes neg., ECG ST-depelmm, Tk +Trop Low risk: Outpatient evaluation Enzymes neg., ECG
more » ... p 2 1 mm* Unstable angina Enyzmes neg., ECG ST 65, old MI) and predischarge stress test*
doi:10.1002/clc.4960241307 fatcat:72o5hul3knbm5etcrfoaakkzym